Documenta Ophthalmologica

, Volume 103, Issue 1, pp 73–79 | Cite as

Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE®) once daily versus timolol maleate ophthalmic solution twice daily

  • Arthur H. Shedden
  • Jean Laurence
  • Andrea Barrish
  • Timothy V. Olah
Article

Abstract

Purpose: The objective of this study was to compare plasma concentrations of timolol following multiple dosing of the therapeutic regimens of timolol maleate ophthalmic gel-forming solution (Timolol GS; TIMOPTIC-XE®) and timolol maleate ophthalmic solution. Timolol maleate ophthalmic gel-forming solution is also referred to as Timolol GS, i.e. gel-forming solution. Methods: This was a masked observer, two-period crossover study in six normal male subjects randomized to receive either Timolol GS, 0.5% (TIMOPTIC-XE,) once daily (0530 hours) or timolol maleate ophthalmic solution (0.5% TIMOPTIC®) twice daily (0530 and 1730 hours) for 8 days, in both eyes. On Day 8, a blood sample was obtained prior to treatment, as well as 1, 2, 4, 8, 10, 12, 13, 14, 16, and 24 hours following the morning instillation. After a 7-day inter-period washout interval, subjects received the opposite treatment. Results: Timolol GS (TIMOPTIC-XE): Plasma concentrations of timolol rarely exceeded 0.375 ng/ml (the lower limit of assay quantification). For all subjects, peak plasma concentrations of timolol averaged <0.3 ng/ml within 4 hours after the last dose. The highest single observation was 0.49 ng/ml in one subject (at hour 2). Timolol solution: For all subjects, peak plasma concentrations of timolol averaged about 0.5 ng/ml and 0.3 ng/ml within 4 hours following the first and second dose, respectively, on Day 8. The highest single observation was 0.95 ng/ml in one subject (at hour 2). Conclusions: The data suggest that there is less systemic exposure to timolol following once-daily therapy with Timolol GS 0.5% compared with twice daily therapy with timolol maleate ophthalmic solution 0.5%.

gel gellan gum plasma levels timolol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Greaves JL, Wilson CG, Rozier A, Grove J, Plazonnet B. Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit. Curr Eye Res 1990; 415-20.Google Scholar
  2. 2.
    Shedden AH. Timolol maleate in gel-forming solution: a novel formulation of timolol maleate.Chibret Intl J Ophthalmol 1994;10:332-6.Google Scholar
  3. 3.
    Laurence J, Holder D, Vogel R, Gross RL, Haik BG, Karp DW, Koby MM, Zimmerman TJ. A double-masked, placebo-controlled evaluation of timolol in gel vehicle.J Glaucoma 1993;2:177-82.Google Scholar
  4. 4.
    Vogel R, Shedden A, Laurence JK, Neafus R and the Study Group for Timolol-in Gelrite Pharmacology. The ocular hypotensive effect of once daily administration of timolol-in-Gelrite (TG) vs. timolol solution (TS).Invest Ophthalmol Vis Sci 1991;32:946.Google Scholar
  5. 5.
    Alvan G, Calissendorff B, Seideman P, Widmark K, Widmark G. Absorption of ocular timolol.Clin Pharmacokinet1980;5:95-100.Google Scholar
  6. 6.
    Passo MS, Palmer EA, van Buskirk EM.Plasma timolol in glaucoma patients.Ophthalmology 1984;91:136-3.Google Scholar
  7. 7.
    Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs.Arch Ophthalmol1984;102:551-3.Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Arthur H. Shedden
    • 1
  • Jean Laurence
    • 1
  • Andrea Barrish
    • 1
  • Timothy V. Olah
    • 1
  1. 1.Merck Research LaboratoriesWest PointUSA

Personalised recommendations